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Abstract: An exchange protein directly activated by cAMP 1 (EPAC1) is an intracellular sensor
for cAMP that is involved in a wide variety of cellular and physiological processes in health and
disease. However, reagents are lacking to study its association with intracellular cAMP nanodomains.
Here, we use non-antibody Affimer protein scaffolds to develop isoform-selective protein binders of
EPAC1. Phage-display screens were carried out against purified, biotinylated human recombinant
EPAC1∆DEP protein (amino acids 149–811), which identified five potential EPAC1-selective Affimer
binders. Dot blots and indirect ELISA assays were next used to identify Affimer 780A as the top
EPAC1 binder. Mutagenesis studies further revealed a potential interaction site for 780A within the
EPAC1 cyclic nucleotide binding domain (CNBD). In addition, 780A was shown to co-precipitate
EPAC1 from transfected cells and co-localize with both wild-type EPAC1 and a mis-targeting mutant
of EPAC1(K212R), predominantly in perinuclear and cytosolic regions of cells, respectively. As a
novel EPAC1-selective binder, 780A therefore has the potential to be used in future studies to further
understand compartmentalization of the cAMP-EPAC1 signaling system.
Keywords: EPAC1; cyclic AMP; affimer; microscopy; protein interactions; phage display
1. Introduction
The universal second messenger, 3′,5′-cyclic adenosine monophosphate (cAMP), was
the first to be discovered in eukaryotic cells in 1958 by Earl Sutherland and colleagues [1].
The cAMP signaling pathway is now considered to be a paradigm of intracellular signaling
and is involved in a wide variety of cellular and physiological processes [2–5]. Activation
of Gs protein-coupled receptors (GsPCRs) promotes activation of intracellular adenylyl
cyclases (AC), leading to the generation of cAMP inside the cell from ATP. Signal termina-
tion occurs through the hydrolytic action of cAMP phosphodiesterase (PDE) enzymes and
receptor desensitization. There are nine membrane-bound, and one soluble, isoforms of
AC, whereas the PDE superfamily is made up of 21 genes, grouped into 11 diverse families
(PDEs 1–11) [6,7].
The downstream signaling effects in response to cAMP production were originally
attributed to activation of protein kinase A (PKA) isoforms [8]. For example, gene transcrip-
tion induced by cAMP is mediated through PKA phosphorylation of the cAMP response
element-binding protein (CREB) transcription factor, amongst others [9]. Subsequently, a
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new cAMP sensor, exchange protein directly activated by cAMP (EPAC) was identified,
showing that the activation of the small GTPase, Rap1, by cAMP occurred independently
of PKA [10,11]. Cyclic nucleotide-gated ion channels (HCN) and Popeye domain contain-
ing (POPDC) gene family are two additional recently discovered cAMP effectors [12–14].
As effector proteins, PKA and EPAC are known to be anchored to specific intracellular
sites by scaffold proteins, which act to maintain compartmentalization of cAMP signaling
by anchoring PDEs adjacent to target effectors and, consequently, regulate the ability of
cAMP to initiate downstream signaling events at discrete subcellular compartments or
nanodomains [15].
Evidence is emerging that compartmentalization of the two EPAC isoforms, EPAC1
and EPAC2, is key to tailoring their effector functions. For example, in vascular endothelial
cells (VECs), VE-cadherin-based adhesion and cell permeability are mediated by PDE4D
regulation of EPAC1 signaling complexes [16]. In the first study to investigate the sub-
cellular localization of EPAC1, two distinct populations of EPAC1 were observed [17] in
EPAC1-GFP transfected COS7 cells, where EPAC1 was localized mainly in and around the
nucleus, along the nuclear membrane, but also in punctate structures identified to be the
mitochondria in these cells [17]. An increase in levels of EPAC1 at the nuclear membrane
was observed in these cells following stimulation with forskolin and rolipram [17]. Im-
portantly, this was the first study to show that the EPAC1 membrane association was due
to the EPAC1 Disheveled-EGL-plekstrin homology (DEP) domain [17]. From this study,
it was further determined that the localization of EPAC1 was cell cycle dependent, with
EPAC1 being mainly associated with the nuclear membrane during metaphase, and then
further associated with the mitotic spindle and centrosomes following the breakdown of
the nuclear envelope [17]. The localization of EPAC1 to the perinuclear region of cells
has also been seen in several other cell lines, including COS1, human embryonic kidney
(HEK293) cells and cancer cell lines, such as the human epidermal carcinoma (A431) and
the human breast cancer (MCF7) cells [17–23]. This is consistent with Rap1 fluorescence
resonance energy transfer (FRET) activation studies that demonstrate activation of Rap1
in this region following elevations in intracellular cAMP [21]. Inactive EPAC1 appears to
be tethered to the nuclear envelope through interactions with the scaffold protein, Ran
binding protein 2 (RanBP2) [24,25], which is a component of the nuclear pore complex,
although the activation/inactivation cycle of EPAC1 at the nuclear/perinuclear region
remains to be determined.
EPAC1 has also been observed, via confocal microscopy, total internal reflection
fluorescence (TIRF) and FRET analysis, to translocate to the plasma membrane (PM) in
HEK293 cells, at early time points following cAMP stimulation [22]. Again, the EPAC1
DEP domain was found to be essential for EPAC1 translocation, but in cooperation with
the catalytic region [22], through interactions with the negatively charged phospholipid,
phosphatidic acid (PA) [26]. This results in the tethering of EPAC1 to the PM, allowing for
Rap1 activation and facilitating cell adhesion [26]. In addition, EPAC1 recruitment to the
PM can occur independently of the DEP domain via interaction of the first 49 residues at
the N-terminus of EPAC1 with the ezrin-radixin-moesin (ERM) family of actin-binding
proteins [27]. When active, ERM proteins, such as ezrin, can bind to EPAC1 and recruit the
protein to PM in clusters, working with DEP-domain mediated translocation to control cell
adhesion [27]. EPAC2 has also been observed to localize at the PM, through interactions
with PM-bound Ras, leading to localized Rap1 activation [23,28,29].
The distinct distributions of the EPAC1 and EPAC2 isoforms have also been studied in
adult mouse cardiomyocytes using a novel fluorescent EPAC ligand, 8-[PharosΦ-cAMP]-
2′-O-methyladenosine-3′,5′-cyclic monophosphate (Φ-O-Me-cAMP) [30]. In these studies,
Φ-O-Me-cAMP offered an advantage over EPAC1- and EPAC2-selective antibodies, which
show a lack of specificity in immunolocalization studies [30]. With Φ-O-Me-cAMP it was
observed that endogenous EPAC2 levels were concentrated at T-tubules while endogenous
EPAC1 was concentrated at perinuclear regions [30]. These different localizations of
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EPAC1 and EPAC2 are no doubt important for their isoform-specific regulation in cells and
consequently their diverse physiological functions.
Despite the emergence of Φ-O-Me-cAMP, there are still very few tools available to
study EPAC1 localization in cells beyond transfection with labelled isoform. There is a
commercially available monoclonal antibody (Ab), 5D3, which was first developed by
the Bos laboratory but is limited in its usefulness because it acts as an allosteric agonist
towards EPAC1 [31]. 5D3 specifically activates EPAC1 by binding to an epitope in the
EPAC1 CNBD that is normally hidden through interactions with the catalytic region [31].
In addition, an EPAC2-specific monoclonal antibody, 5B1, has also been developed, with
its epitope shown to be in a similar area of the EPAC2 CNBD as 5D3 [31]. Whereas 5D3
can be used for immunoprecipitation and immunofluorescence studies, 5B1 is unable to
precipitate EPAC2 from cells [31]. Furthermore, in a study by Parnell et al., it was confirmed
through IP studies that the 5D3 Ab selectively recognized the active conformation of EPAC1
in HEK293T cells transfected with FLAG tagged EPAC1, as well as the inactive form of
the protein [23]. The companies Abcam and Santa Cruz both sell EPAC1- and EPAC2-
selective monoclonal and polyclonal antibodies, which have been used in several different
studies. For example, a recombinant anti-EPAC1 antibody from Abcam (Cat. no. ab109415)
has been used in Western blotting to detect EPAC1 levels in human retinal endothelial
cells (RECs) following EPAC1-agonist treatment [32]. While antibodies can be used for
immunocytochemistry (ICC) or immunohistochemistry (IHC), current EPAC antibodies
may not be useful for immunolocalization studies due to non-specific interactions; hence
the mouse monoclonal EPAC1-A5 (Santa Cruz), goat polyclonal EPAC1-N16 (Abcam)
and rabbit polyclonal anti-EPAC1 (Abcam) antibodies all gave a strong positive signal in
immunocytochemistry of double knockout EPAC1 and EPAC2 mouse cardiomyocytes [30].
Thus, the current available antibodies for ICC/IHC may not be specific enough for definite
localization of EPAC isoforms in cells [30].
An increasingly utilized alternative to antibody-based reagents are engineered proteins
such as the peptide aptamer scaffolds, or Affimers, developed by Avacta Life Sciences
(Wetherby, United Kingdom). These are small (12–15 kDa; 2–4 nm), monomeric, single-
domain recombinant proteins of ~98 amino acids [33]. Affimers are selected from a library
in which two loops between adjacent pairs of β-strands at one end of the domain each
contain a variable sequence of nine amino acids [33,34]. These two loops typically constitute
the site by which they interact with their targets. Besides being small, Affimers have
several other advantages over antibodies. They are structurally stable, even under the
harshest conditions, and lack disulfide bridges. Affimers do not require post-translational
modification, nor do they have cysteine residues, allowing efficient expression in E.coli. In
addition, they have excellent thermal and chemical stabilities with a pH range of 2–13 and a
melting temperature of 101 ◦C. In addition, they can be easily conjugated with reporter tags
or drugs [33]. Furthermore, the two variable loops provide versatile design opportunities
as the two insert sequences can be randomized, allowing for identification of Affimers with
desired affinity and specificity for specific targets that can be quickly generated using an
established phage-display library (>6 × 1010) [33].
In this study, we used the non-antibody Affimer technology to develop a selective
probe that can recognize the cAMP sensor, EPAC1, for the purpose of biochemical and
microscopy studies. Here, we describe the identification of EPAC1-selective Affimers from
phage-display screens, their characterization in protein binding assays, further identifi-
cation of an Affimer interaction site in the CNBD of EPAC1 and proof-of-principle use
of an EPAC1 Affimer binder in co-immunoprecipitation and co-localization studies in
transfected cells.
2. Materials and Methods
2.1. Materials
Acrylamide/Bis-acrylamide, 30% (v/v) solution, Ammonium-15N chloride, Ampicillin
sodium salt, Adenosine 3′,5′-cyclic monophosphate (cAMP), Adenosine 5′-triphosphate
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disodium salt hydrate (ATP) 3,3′,5,5′-Tetramethylbenzidine Liquid Substrate, Benzami-
dine Sepharose 4Fast Flow (High sub), cOmplete™ Protease inhibitor cocktail, Forskolin,
Helmanex™ III, ISOGRO®-15N Powder, Kanamycin sulfate, L-Glutathione reduced, N, N,
N′, N′-tetramethylethylenediamine (TEMED), Pefabloc® SC, Poly-D-Lysine hydrobromide
(PDL), PreScission® Protease, SYPRO® Orange Protein Gel Stain and Thrombin Protease
were from Sigma-Aldrich (Dorset, UK). 5,7-Dibromo-6-fluoro-3,4-dihydro-2-methyl-1(2H)-
quinolinecarboxaldehyde (CE3F4) was from Tocris (Bristol, UK). Alfa Aesar™ Ponceau
S, BL21 Star (DE3) One Shot Chemically Competent E.coli, Biotium Covergrip Cover-
slip Sealant, Bovine Serum Albumin (BSA), DL-1,4-Dithiothreitol (DTT), Dimethyl Sul-
foxide (DMSO), EZ-Link™ Sulfo-NHS-LC-Biotin, Isopropyl-β-D-thio-galactopyranoside
(IPTG), Lipofectamine 3000 Transfection Reagent, Lipofectamine™ LTX Reagent with
PLUS™ Reagent, PageBlue Protein staining solution, Phosphate-Buffered Saline (PBS)
Tablets (10 mM sodium phosphate, 2.68 mM potassium chloride, 140 mM sodium chloride,
pH 7.45), Prolong Glass Antifade Mountant and SuperSignal™ West Pico chemiluminescent
substrate were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 8-(2-[7-Nitro-
4-benzofurazanyl]aminoethylthio) adenosine-3′,5′-cyclic monophosphate (8-NBD-cAMP)
and 8-pCPT-2′-O-Me-cAMP (D-007) were purchased from Biolog LSI (Bremen, Germany).
5-alpha-Competent E.coli, BL21 (DE3) Competent E.coli, Protein G Agarose Beads, Protein
G Magnetic Beads, Prestained protein standard Marker Broad Range (11–190 kDa) and
RIPA Buffer (10×) were from New England Biolabs (Hertfordshire, UK). His-Tag (27E8)
(Magnetic Bead Conjugate) and His-Tag (27E8) (Sepharose® Bead Conjugate) were pur-
chased from Cell Signaling Technology (Danves), MA, USA). Nitrocellulose membranes
were purchased from Bio-Rad Laboratories Ltd. (Hertforshire, UK).
2.2. Protein Purification
Colonies from stock plates of transformed E.coli bacteria expressing recombinant
EPAC1∆DEP, EPAC1∆DEP mutants (L273W, D276R, R279L and F300D; provided by Pro-
fessor Holger Rehmann, Hochschule Flensburg, Germany), EPAC2∆DEP, or EPAC1-CNBD
were used to inoculate LB-Broth supplemented with 100 µg/mL ampicillin (or kanamycin
for EPAC1∆DEP mutants) and left to grow overnight with shaking (200 RPM) at 37 ◦C.
These pre-cultures were then diluted 1:20 in LB-Broth supplemented with 100 µg/mL
appropriate antibiotic and then incubated for a further four hours (37 ◦C with shaking)
until an optical density reading at 600 nm (OD600) reached two (Biochrom WPA S1200+
Visible Spectrophometer). To induce the expression of GST-tagged proteins, fresh isopropyl-
β-D-thio-galactopyranoside (IPTG) was added to a final concentration of 100 µM and then
the cultures were left to grow O/N at 19 ◦C with shaking. To extract GST-fusion pro-
tein, pellets were resuspended in 25 mL of lysis buffer (50mM Tris-HCl, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 5% (v/v) glycerol) per pellet, supplemented with 0.5 mg/mL lysozyme,
0.1% (v/v) Triton-X 100 and cOmplete Protease inhibitor cocktail (1 tablet/50 mL)). Cells
were then lysed by sonication (SONICS Vibra-Cell™ VCX 130 Ultrasonic Liquid Processor,
SONICS) for three minutes (15 s on, 15 s off) at 65% amplitude on ice. Bulk protein purifi-
cation was then carried out using a previously devised protocol [35] for batch absorption
of GST-tagged protein to pre-equilibrated glutathione Sepharose 4B beads (GS4B). The
GST-tag was removed from purified proteins by adding 80 U of thrombin and incubating
for four hours at 4 ◦C in a sealed column. Pefabloc was added to the collected eluate to
a final concentration of 1 mM to block further thrombin activity. For further purification
of EPAC1 proteins, and to remove any degraded, low-molecular-weight cleaved forms of
EPAC1, the combined cleaved protein fractions were loaded onto a gel filtration column
(HiLoad 16/600 Superdex 200 pg, ÄKTA, GE Healthcare) equilibrated with GFC buffer
(PBS; 150 mM NaCl, 2.5% (v/v) glycerol). The fractions of ÄKTA purified EPAC1∆DEP
protein were combined and analyzed by SDS-PAGE and PageBlue staining or Ponceau-
S staining. Protein concentrations were determined using A280 aliquots were stored at
−80 ◦C.
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2.3. Biotinylation of EPAC1∆DEP Protein
Purified EPAC1∆DEP was biotinylated using amine reactive Biotinylation reagent,
EZ-Link™ Sulfo-NHS-LC-biotin (Thermo Fisher Scientific, Waltham, MA, USA) in a 10-
fold molar excess for 2 h on ice. Excess biotin was removed by diafiltration into PBS,
pH 7.4. Successful biotinylation was confirmed using Western blotting developed with
Streptavidin-HRP (ab7403; Abcam, Cambridge, UK).
2.4. Phage-Display Screens
Phage screens were performed using a Type II Affimer library, T2[9_9]ph4v1 (Avacta
Life Sciences, Wetherby, United Kingdom). Up to three rounds of panning were performed
during each screen. During two selections, EPAC1 was immobilized alone (S01, S04) and
additional selections were performed with either 10 µM D-007 (EPAC1-agonist) (S02, S05)
or 10 µM CE34F (EPAC1-antagonist) (S03, S06) in the buffer (PBS, pH 7.4). All phage
selections consisted of three panning rounds. Bound phage were used to infect E.coli
cells and then plated. The Affimer protein coding regions from each phage screen were
subcloned into a vector containing both HA and His6 tags (pEtLECTRA cHAH6) and
transformed into E.coli. 90 positive colonies were taken from pans two and three of each of
the six phage selections (S01-S03; S04-S06; 1080 in total). Each colony was grown overnight
and the resulting candidate Affimer proteins were purified by immobilized metal affinity
chromatography. The concentrations of the purified Affimer proteins were normalized to
2.5 µg/mL for use during primary screening.
2.5. Orthogonal Screening of Identified Affimer Clones
HA-tagged Affimers from the 90 selected clones from phage-display screens were
screened in multiple independent bead-based multiplex binding assays using a flow cy-
tometer Intellicyt iQue instrument to confirm their interaction with biotinylated
EPAC1∆DEP. The iQue screening platform is a bead-based flow system for quick analysis
of clones against a multiplexed target set. Biotinylated EPAC1∆DEP and mIgG2b (positive
control) were immobilized to streptavidin-functionalized beads, in the presence of 10 µM
D-007 (EPAC1-agonist) or 10 µM CE34F (EPAC1-antagonist) in the final assay solution.
The HA-tagged Affimers interacting with bead-bound EPAC1∆DEP were detected using
anti HA-tag antibodies with an AlexaFluor 488 conjugate. Similarly, the immobilized
mIgG2b positive control was detected with and anti-mIgG2b HA tagged Affimer (G12)
followed by Alexa-fluor-conjugated anti-HA-tag antibodies. Affimers found to interact
with immobilized EPAC1∆DEP were further tested for cross-reactivity by testing their
interaction with bead-immobilized human and dog C-reactive protein (CRP) and/or anti-
carcinoembryonic antigen (CEA). Affimers displaying no cross-reactivity were sequenced
and used in follow-on assays.
2.6. Dot Blotting
Different concentrations of recombinant EPAC1∆DEP (GST-tag free) were spotted
onto nitrocellulose membranes. Antibody/Affimer interactions were then detected by
far-Western blotting. The membranes were blocked for one hour at RT with 5% (w/v)
“Marvel” milk (antibody blot) or BSA (Affimer blot) in 1 × TBST followed by a two-hour
incubation at RT in either 4.5 nM (1:1000) of 5D3 antibody in 5% (w/v) milk in 1 × TBST, or
45 nM of Affimer diluted in 5% (w/v) BSA in 1× TBST. Membranes were then incubated for
one hour at RT with an appropriate secondary antibody (anti-mouse for 5D3 antibody or
His-tag for Affimer) and the protein signal was detected with ECL (SuperSignal™ West Pico
chemiluminescent substrate; Thermo Fisher Scientific, Waltham, MA, USA) and visualized
using a Fusion FX imaging system.
2.7. Microscale Thermophoresis (MST)
The Monolith NT™ Protein Labelling Kit Red-NHS containing the red fluorescent
dye NT-647 was used to label recombinant EPAC1-CNBD protein according to the man-
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ufacturer’s protocol. Equal volumes of labelled protein were then added to Monolith
NT.115 capillaries (Nanotemper technologies) and then measured at LED/excitation set at
80–100% and MST power of 60% (high setting) on the MST instrument. The normalized
fluorescence (Fnorm (%)) from MO.Affinity Analysis software version 2.2.4 (Nanotemper
technologies) was normalized as a fold change with the relative fluorescence associated
with the lowest concentration of antibody set to 1 (Arbitrary Units: AU). The pEC50 was de-
termined by nonlinear curve fitting analysis (Log (agonist) vs. response (three parameters))
GraphPad Prism.
2.8. Protein Interaction ELISA Assays
GST-tagged recombinant proteins (1 µg/100 µL/well) were added to Pierce™ glu-
tathione coated plates (15,140; Thermo Fisher Scientific), and incubated overnight at 4 ◦C.
100 µL/well of 0.002–0.250 µM 5D3 or 5B1 antibody, or 0.004–4 µM of Affimer was then
added and incubated for one hour at RT. 100 µL/well of 1:10,000 anti-mouse or anti-his-tag
HRP-conjugated secondary antibodies were then added to 5D3/5B1 antibody or Affimer
wells, respectively, and incubated for a further one hour at RT. Recombinant protein alone
was used as a control. Each experiment was performed in triplicates and between each in-
cubation step, the wells were washed three times with wash buffer (10 mM Tris-HCl pH 7.4,
150 mM NaCl and 0.05% (v/v) Tween-20 buffer). Protein, antibodies and Affimers were
diluted in assay buffer (10 mM Tris-HCl pH 7.4 and 150 mM NaCl buffer). Plates were kept
covered during all incubation steps. Finally, 100 µL/well of 3, 3′,5,5′-Tetramethylbenzidine
Liquid (ELISA) Substrate, Supersensitive was added to each well and incubated for 30 min
at RT. Detection of color change was measured at wavelength 655 nm using a FLUOstar
Omega Microplate reader (BMG Labtech, Aylesbury, Bucks, UK). All data were normal-
ized as a fold change where the lowest concentration of antibody or Affimer was set to 1
(arbitrary units).
2.9. Thermal Shift Assays (TSA)
Thermal shift assays were carried out in Thermo Fisher Scientific™ Abgene 1.2 mL
Polypropylene 96-well storage plates (10243223; Thermo Fisher Scientific, Waltham, MA,
USA), using a modified protocol based on the methods described by Huynh and Partch [36].
All dilutions were prepared in assay buffer (50 mM Tris-HCl pH 7.5, 50 mM NaCl, 2.5% (v/v)
glycerol and 5 mM DTT). 1–2 µg/well of GST-tagged recombinant protein was combined
with 20 × SYPRO Orange dye and added to wells. Plates were sealed with a sheet
of optically clear adhesive (MicroAmp™ Optical Adhesive Film; Applied Biosystems)
and mixed for 15 min on an orbital shaker at RT before incubating overnight at 4 ◦C.
The fluorescence readout of SYPRO Orange dye was then measured using an Applied
Biosystems StepOnePlus Real-time PCR Instrument (System Version 2.2.3; Thermo Fisher
Scientific) with excitation wavelength 470 nm and emission wavelength 570 nm over a
temperature range from 11 to 80 ◦C ramped in 0.5 ◦C increments with plateau times of 30 s.
The melting temperature (Tm) (◦C) was derived from calculating the first derivative of the
fluorescence emission as a function of temperature (−dF/dT) (Equation (1)) where Tm is
the lowest first derivative value. For multiple experimental replicates, the mean Tm was
calculated with standard error of the mean.
Equation (1). First Derivative Calculations.
dF = F (fluorescence emission) − T (temperature)
dT = Tx − Tx (e.g., T2 − T1)
−dF/dT = −(dF ÷ dT)
(1)
2.10. Cell Culture
COS1 cells were grown in Dulbecco’s modified Eagle’s medium (without added
glutamine) (DMEM), 10% (v/v) fetal bovine serum, 2 mM glutaMAX, and 100 units/mL
and 100 µg/mL penicillin and streptomycin, respectively. Cultures were incubated at
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37 ◦C, 5% (v/v) CO2. U20S cell lines stably expressing pBabe-Flag-Epac1 (HS 1-881) (EPAC1
U2OS), pBabe-Flag-Epac2 (EPAC2 U2OS) or vector alone (Control U2OS), were gifts from
Professor Holger Rehmann (Hochschule Flensburg, Germany). U2OS cells were grown
in Dulbecco’s modified Eagle’s medium (without added glutamine) (DMEM), 10% (v/v)
fetal bovine serum, 2 mM glutaMAX, and 100 units/mL and 100 µg/mL penicillin and
streptomycin, respectively and incubated at 37 ◦C, 5% (v/v) CO2. Puromycin (2 mg/L (w/v))
was added to growth medium to maintain stable expression of EPAC1 and EPAC2 U2OS
cell lines only.
2.11. SDS-PAGE and Immunoblotting
Equal amounts of recombinant proteins or cell lysates were separated on 8, 10, 12
or 12.5% (w/v) SDS-PAGE gels, depending on protein size, by electrophoresis. Lysates
were then wet transferred from gels to nitrocellulose membranes using Mini Trans-Blot®
electrophoretic transfer cell (Bio-Rad) and 1x transfer buffer (250 mM Tris Base, 1.92 M
Glycine) for one hour and 30 min at 80 V. Membranes were then blocked in 5% (w/v)
“Marvel” milk powder in 1 × TBST (100 mM Tris-HCl, pH 7.4, 59 mM NaCl, 0.1% (w/v)
Tween-20) for one hour at RT. Primary antibodies diluted in 1 × TBST were incubated
overnight at 4 ◦C followed by a one hour incubation at RT with the secondary antibody
diluted in 1 × TBST. Protein signals were detected using ECL (SuperSignal™ West Pico
chemiluminescent substrate) and visualized using Fusion FX imaging software (Vilber
Lourmat, France).
2.12. Immunoprecipitation (IP)
U2OS cells were grown to 100% confluency in 6-well plates (9.6 cm2 per well) and
then placed on ice and washed with 1 mL/well ice-cold PBS. Cells were then lysed with
0.5 mL/well lysis buffer (1x RIPA buffer supplemented with 1× complete Protease inhibitor
cocktail). Cell lysates were subjected to immunoblotting with 5D3 mAb (1.35 or 2.6 µg),
5B1 mAb (2.5 µg), rabbit IgG (4 µg) antibodies or unbound Affimer either alone (2.6 µg)
and incubated with rotation for 30 min at 4 ◦C. Protein G Agarose or α-His Tag Sepharose®
beads were then added and incubated with rotation for one hour at 4 ◦C. Beads were then
collected by centrifugation and heated in 1x sample buffer for five minutes at 95 ◦C. The
input and immunoprecipitated samples were then analyzed by Western blotting.
2.13. Immunofluorescent Confocal Microscopy
COS1 cells were seeded to at least 90% confluency onto PDL-coated 25 mm diameter
No 1.5H high-precision glass coverslips and allowed to adhere overnight in growth medium
(37 ◦C, 5% (v/v) CO2). Cells were then transiently co-transfected with 780A-mCherry
DNA and EPAC1-FLAG or EPAC1-(K212R)-FLAG. Cells were then transfected with X-
tremeGENE 360 (XTG360) Transfection Reagent (Sigma-Aldrich) as per the manufacturer’s
protocols. To check the transfection efficiency wide-field imaging was carried out on
FLoid™ Cell Imaging Station (Thermo Fisher Scientific 4471136), normal white light and
red or green fluorescence were used. After 48 h, growth medium containing transfection
reagents was replaced with fresh medium and coverslips were incubated for 30 min at
37 ◦C, 5% (v/v) CO2. Cells were then stimulated or unstimulated with 100 µM of 007 and
incubated for 15 min at 37 ◦C, 5% (v/v) CO2 before fixation with 2 mL/well of 4% (v/v)
paraformaldehyde (prepared in PBS) for 15 min at RT. Cells were then quenched to remove
free aldehydes with 2 mL/well of filter sterilized (Whatman Puradisc 25 mm syringe filter
0.2 µm) 50 mM NH4Cl (prepared in PBS) for 10 min at RT. Cells were then permeabilized
with 2 mL/well of 0.1% (v/v) Triton-x 100 in PBS for 10 min at RT. Cells were washed
three times with PBS between each incubation. Cells were then blocked for one hour at
RT in blocking buffer (1% (w/v) BSA, 0.3% (v/v) Triton-X 100 in PBS, filtered (Whatman
Puradisc 25 mm syringe filter 0.2 µm)). Primary and secondary antibodies (α-FLAG and
goat α-mouse IgG H + L (Alexa Fluor 488)) were prepared in blocking buffer and cells were
incubated for one hour at RT. Coverslips were mounted onto Fisherbrand™ microscopic
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glass slides (12383118; Thermo Fisher Scientific) using Prolong™ Glass Antifade Mountant,
sealed with Biotium covergrip coverslip sealant and stored at 4 ◦C. Samples were analyzed
using a Leica HC PL APO C52 63x water objective on a Leica TCS SP8 STED 3 × confocal
microscope. Samples were excited using a Supercontinuum White Light Laser at 488 and
580 nm for Alexa Fluor 488 and mCherry, respectively, using a Leica HyD1 hybrid detector
with detection windows of 500–550 nm for Alexa Fluor 488 and 590–650 nm for mCherry.
2.14. Data Analysis
Calculations were performed using Microsoft Excel 2016 for Windows (Microsoft
Software) and graphs were made using GraphPad Prism version 5.2 or 8.4.2 for Windows
(GraphPad Software LLC, San Diego, CA, USA). Unless otherwise stated, data values are
represented as the mean ± standard error of the mean (SEM) or the mean ± standard
deviation (SD). The density of protein bands from Western blots was quantified using
ImageJ/Fiji version 1.53c (National Institute of Health, Bethesda, Maryland, USA).
To compare two sets of means with a minimum of three experimental repeats, p-values
were obtained from unpaired t-tests using GraphPad Prism version 5.2/9.0.0 for Windows.
Analysis of variance (ANOVA) was used for data sets with three or more sets of means,
with a minimum of three experimental repeats. p-values were from one-way ANOVA with
Dunnett’s multiple comparison test using GraphPad Prism versions 5.2/9.0.0.
Confocal images were acquired using the Leica Application Suit X software version
3.0.15 and saved in the LIF format and analyzed using ImageJ/Fiji. Z-stacks were taken
with a zoom factor of 1.3 (2048 × 2048 nm). Deconvolution was performed using Huygens
Professional software using default settings apart from 0.01% quality change threshold
and images were saved in the ICS image format and analyzed using ImajeJ/Fiji. Scale bars
were added to microscopy images using the ImageJ Microscopy Scale plugin (National
Institute of Health, Bethesda, Maryland, USA). Using ImageJ/Fiji, Z-stacks were analyzed
using the Stacks Z-project maximum intensity projection method. Brightness and contrast
adjustments post-acquisition were performed using ImageJ/Fiji.
3. Results
3.1. Phage-Display Selection Using EPAC1∆DEP as a Target for Affimer Production
In order to generate Afimers against EPAC1, we purified recombinant EPAC1∆DEP
to homogeneity, based on a previously devised protocol [36]. EPAC1∆DEP was then
biotinylated using an amine-reactive biotinylation reagent as described in Materials and
Methods (Figure 1). To identify EPAC1-directed Affimers that bind selectively to either the
active form (agonist 007-bound), inactive form (antagonist CE3F4-bound) or the ligand-free
forms of EPAC1∆DEP, six separate in vitro phage-display screens against biotinylated
EPAC1∆DEP were carried out using Avacta’s standard double loop type II library (Table 1).
From these screens, 9 positive binders were identified that interacted with biotinylated
EPAC1∆DEP, irrespective of the presence or absence of the EPAC1 agaonist, 007, or the
EPAC1 antagonist, CE3F4. To confirm positive interaction with EPAC1∆DEP, the nine
Affimers, identified from the phage-display screens, were re-screened using a bead-based,
fluorescent assay (iQue assays, Figure 2). From these assays, five strong Affimer binders
were identified, 380A, 414A, 691A, 748A and 780A, which showed a significant increase
in binding to EPAC1∆DEP, compared to no Affimer control (Figure 2). Affimer 380A
was identified as being consistently the strongest EPAC1∆DEP-selective Affimer binder,
while 414A was consistently the weakest of the five (Figure 2). There was a significant
increase in binding of all five Affimers to EPAC1∆DEP in the presence of 007 but no
significant differences in binding were observed in the presence of CE3F4 (Figure 2).
Therefore, through the functional assessment of EPAC1∆DEP-selective Affimers identified
from the phage-display screens detailed in Table 1, Affimers with weak affinities and/or
cross-reactivity negative control proteins were deselected. This gave rise to five unique
Affimers, 380A, 414A, 691A, 748A and 780A, that were identified as selective binders for
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EPAC1∆DEP and whose interaction was enhanced in iQue assay in the presence of the
EPAC1 agonist, 007.
Figure 1. Biotinylation of EPAC1∆DEP protein. EPAC1∆DEP-GST protein was expressed and
purified from E.coli and the GST removed by limited proteolysis (left panel). EPAC1∆DEP was then
biotinylated as confirmed by SDS-PAGE and Coomassie staining (center panel) and Western blotting
(right panel). SeeBlue Plus2 protein markers were used for size comparison.
Table 1. Summary of phage-display selection methods. Six different phage-display screens were carried out using
biotinylated EPAC1∆DEP as a target (screens S01–S06). Pre-panning deselection and off-rate deselection was performed
in pans 2 and/or 3 as a process of negative selection. Here, homologous proteins, (EPAC1∆DEP with no ligand) were
premixed with the phage library, either as immobilized proteins and/or as proteins in solution. Off- rate deselection
involves allowing the Affimer-expressing phage to bind to the target, washing away unbound phage and incubating the
phage bound to immobilized target overnight in buffer before eluting the following morning; this drive selection towards
Affimer proteins with the slowest off-rates. Enrichment refers to the number of captured phage with affinity for biotinylated








S01 EPAC1∆DEP None In pans 2 and 3 9 × over neutravidin
S02 EPAC1∆DEP plus 007 EPAC1∆DEP in Pans 2 and 3 In pans 2 and 3 1.2 × over EPAC1∆DEP
S03 EPAC1∆DEP plus CE3F4 EPAC1∆DEP in Pans 2 and 3 In pans 2 and 3 1.2 × over EPAC1∆DEP
S04 EPAC1∆DEP None In pan 3 ~2 × over neutravidin
S05 EPAC1∆DEP plus 007 EPAC1∆DEP in Pans 2 and 3 Not performed 2.5 × over EPAC1∆DEP
S06 EPAC1∆DEP plus CE3F4 EPAC1∆DEP in Pans 2 and 3 Not performed 1.4 × over EPAC1∆DEP
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Figure 2. Assessment of Affimers binding to EPAC1∆DEP in the presence or absence of agonist and antagonist. Affimer
binding to biotinylated EPAC1∆DEP protein was determined by iQue assay, in the presence and absence of 10 µM 007
(EPAC1 agonist) or 10 µM CE3F4 (EPAC1 antagonist). Data were normalized to the median fluorescent intensity of the
positive control Affimer (Affimer G12 against immobilized mIgG2b), which was set to 100%. Significant increases in binding
were determined by one-way ANOVA. Relative differences in binding relative to EPAC1∆DEP plus 10 µM 007, are indicated;
* p < 0.05; ** p < 0.001 and *** p < 0.0001, respectively (n = 3). Results are presented as the means ± SD (n = 3). ns: Not
significant.
3.2. In Vitro Interaction of Isolated Affimers with EPAC1∆DEP
To confirm interaction of identified Affimers with non-biotinylated EPAC1 in solid
phase assays, 1–10 ng or 0.1–1 µg of recombinant EPAC1∆DEP protein were spotted onto ni-
trocellulose membranes and then incubated with either the EPAC1-selective antibody mAb
5D3 or the test Affimers from Figure 2 and then probed with HRP-conjugated anti-mouse
or anti-His tag secondary antibodies, respectively. Protein–antibody/Affimer interactions
were then detected by ECL. From these dot blots, it could be seen that the EPAC1 anti-
body was able to detect all three concentrations of EPAC1∆DEP protein (Figure 3) and, as
EPAC1∆DEP protein concentration decreased, so did the antibody signal (Figure 3).
In terms of Affimer binding, the top three binders, in descending order, were 780A,
380A and 414A, since they showed distinct binding to EPAC1∆DEP protein at all three
concentrations (Figure 3). 748A and 691A, in contrast, were very weak binders and were
unable to detect 100 ng of protein (Figure 3). Ultimately, the EPAC1-specific antibody, mAb
5D3, appears to be a better binder to recombinant EPAC1∆DEP in this assay as protein
signal was much higher at only 10 ng of both recombinant proteins in contrast to 780A
signal when bound to 1 µg of EPAC1∆DEP protein (Figure 3). Nevertheless, from the dot
blot results, the top three Affimer binders to EPAC1∆DEP were identified as being 780A,
380A and 414A, with Affimer 780A representing the top binder.
Having determined that 780A is the most effective binder to EPAC1∆DEP of the Af-
fimers tested, protein interaction ELISA assays were used to determine the relative affinity
of 780A for interaction with recombinant EPAC1∆DEP and EPAC2∆DEP (Figure 5). We
first validated that protein ELISAs were suitable for affinity measurements by comparing
the binding affinities of the commercially available EPAC1 antibody (mAb 5D3) to recom-
binant EPAC1 proteins by comparing MST results with and ELISA results and found that
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both techniques gave comparable pEC50 values (Figure 4) for the binding of 5D3 to the
EPAC1 CNBD (MST) and EPAC1∆DEP (ELISA). Similarly, Affimer 380A binding to the
EPAC1 CNBD gave similar results, in terms of relative EC50s, using both MST and ELISA
approaches. Due to this, we decided to use the ELISA approach in subsequent experiments
due to problems with labelled, full-length EPAC1∆DEP aggregating at high concentrations
in MST experiments.
Figure 3. Dot blotting of anti-EPAC1 antibody and Affimer binding to recombinant EPAC1∆DEP
protein. Recombinant EPAC1∆DEP protein was spotted onto nitrocellulose membranes as indicated.
Membranes were then blocked for one hour in 5% (w/v) milk or BSA in TBST followed by two hours
incubation with either (A) 4.5 nM of anti-EPAC1-antibody (mAb 5D3) in 5% (w/v) milk in TBST or
(B) 45 nM of Affimer (780A, 380A, 414A, 691A and 748A) in 5% (w/v) in TBST. Membranes were
then incubated for one hour with either anti-mouse IgG-HRP, for mAb 5D3, or anti-His-tag HRP, for
Affimer, secondary antibodies. All incubations were performed at room temperature. Protein signals
were detected by ECL and visualized by Fusion FX imaging software. The image is representative of
an experiment carried out on three separate occasions.
We therefore used ELISA assays to compare 780A binding with mAb 5D3 and a com-
mercially available EPAC2-specific antibody (mAb 5B1) as positive controls (Figure 5). For
this, GST-tagged forms of recombinant EPAC1∆DEP and EPAC2∆DEP were immobilized
to GSH-coated plates and then incubated with various concentrations of Affimer 780A or
mAbs. From these dose–response curves, the pEC50 values for mAb 5D3 and Affimer 780A
binding to EPAC1∆DEP protein can be determined (Table 2). Although saturation of the
binding of 780A to EPAC2∆DEP could not be determined, a pEC50 of approximately 9 was
obtained for mAb 5B1 binding to this protein (Table 2). With a pEC50 of approximately
9, mAB 5D3 was a significantly (p < 0.05) more effective EPAC1∆DEP binder than 780A
which had a pEC50 of approximately 6 (Table 2). In addition, from ELISA results, Affimer
780A was identified to have a higher affinity for EPAC1-CNBD over Affimer 380A (Table 2).
Moreover, Affimer 780A bound to both recombinant EPAC1∆DEP and EPAC1-CNBD
proteins but did not bind to either recombinant form of the EPAC2 protein.
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Figure 4. Relative binding affinities of anti-EPAC1 antibody (mAb 5D3) to recombinant EPAC1-CNBD
or EPAC1∆DEP using microscale thermophoresis (MST) and ELISA. (A) Recombinant EPAC1-CNBD
protein was labelled for MST as described in Materials and Methods using the Monolith NT™
Protein Labelling Kit RED-NHS and then diluted to 20 nM with assay buffer. A serial dilution
of mAb 5D3, ranging from 0.03 to 125 nM, was also prepared in assay buffer, and then added to
16 capillary tubes containing equal volumes of target protein. Samples were then measured by Mono-
lith NT1.15 (Nanotemper) at LED/excitation set to 80–100% and MST power of 60% (high setting).
(B) A 1 µg/well of recombinant EPAC1∆DEP protein added to glutathione-coated plates and incu-
bated overnight at 4 ◦C. Serial dilution of 5D3 Ab (0.2–125 nM) was prepared in assay buffer and
incubated for 1 h at RT. Anti-mouse antibody (1:10,000) was then added and incubated for a further
1 h at room temperature. The ELISA substrate was added and absorbance measurements at 655 nm
were taken after a 30 min incubation at room temperature using a FLUOstar Omega Microplate reader.
The experiments were performed in triplicates. Data for both MST and ELISA were normalized as a
fold change with the relative fluorescence associated with the lowest concentration of antibody set
to 1 (Arbitrary Units (AU)). Error bars are representative of the standard error of the mean (n = 4)
and pEC50 (mean ± SEM) was determined by using Log (agonist) vs. response-variable slope (four
parameters) regression curve fitting (Graphpad Prism).
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Figure 5. Relative binding affinities of Affimer 780A versus anti-EPAC1- (mAb 5D3) and anti-EPAC2-
selective (mAB 5B1) antibodies for recombinant EPAC1∆DEP and EPAC2 ∆DEP proteins. For each
ELISA, 1 µg/well of GST-tagged recombinant protein, either A) EPAC1∆DEP or B) EPAC2∆DEP
was added to glutathione-coated plates and incubated overnight at 4 ◦C. Serial dilutions of His-
tagged Affimer (780A) (0.004–4 µM) or antibodies (A) mAb 5D3 and (B) mAb 5B1 (0.2–125 nM)
were then incubated for one hour at RT. Anti-His-tag or anti-mouse antibodies (1:10,000) were then
added to the Affimer or antibody-containing wells, respectively, and incubated for a further one
hour at room temperature. The ELISA substrate was then added and absorbance measurements at
655 nm were taken using a FLUOstar Omega Microplate reader. The experiments were performed
in triplicates. Data were normalized as a fold change with the relative fluorescence associated with
the lowest concentration of Affimer or antibody being set to 1 (Arbitrary Units (AU)). Error bars are
representative of the standard error of the mean (n = 1–5) and the Log (agonist) vs. response—variable
slope (four parameters) nonlinear regression curve fitting was used to obtain pEC50 (GraphPad
Prism). A significant decrease in binding efficacy (Emax) relative to EPAC1∆DEP plus 5D3 Ab
(# p < 0.0005) was determined by unpaired t-test (GraphPad Prism).
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Table 2. pEC50 values from ELISA and MST binding assays. The pEC50 (negative log of the EC50) values of either Affimer
(780A or 380A) or antibody (mAb 5D3 or mAb 5B1) when binding to different recombinant EPAC proteins were determined
by ELISA or MST. The binding of Affimer to EPAC2∆DEP and EPAC2-CNBD could not be determined because complete





























- - 8.68 ± 0.72 6.39 ± 0.24 -
3.3. Mapping of Affimer Interaction Sites on EPAC1
In order to identify where Affimer 780A binds on EPAC1, ELISAs were performed
using four EPAC1∆DEP point mutants, L273W, D276R, R279L and F300D (Figure 6), which
had previously been identified as being important for mAb 5D3 binding to the CNBD
of EPAC1 [31]. Before proceeding with protein interaction ELISA assays, we first used
thermostability assays to determine if the test proteins purified from E.coli were properly
folded (Figure 7). Comparative Tms from these results demonstrated that the mutant
F300D does not fold properly and that a Tm could not be calculated for this mutant.
Mutant F300D was therefore excluded from further protein interaction assays. Although
conformational changes were also apparent for mutants L273W and D276R, in comparison
to WT EPAC1∆DEP (Figure 7), these proteins appeared to fold correctly. Mutant R279L
showed a comparable Tm to WT EPAC1∆DEP (Figure 7) and was therefore judged to be
correctly folded.
Figure 6. EPAC1∆DEP structure and sequence alignment. Domain organization of recombinant
EPAC1∆DEP. CNBD, cyclic nucleotide binding domain; REM, Ras exchange motif; RA, Ras associ-
ation domain; CDC25-HD, CDC25-homology domain. A sequence alignment of the region in the
CNBD (amino acids 260–300) from wild-type (WT) EPAC1∆DEP with the four mutant forms of the
protein shown. Original and mutated residues are highlighted in bold in each sequence.
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Figure 7. Thermal shift profiles of recombinant wild-type EPAC1∆DEP in comparison to mutant EPAC1∆DEP proteins.
Thermal shift assays were performed using 1 ug of recombinant EPAC1∆DEP wild-type (WT) or mutant (L273W, D276R,
R279L, F300D) protein per well. Plates were incubated overnight at 4 ◦C. with SYPRO Orange dye and then (A) fluorescence
readouts were measured using an Applied Biosystems StepOnePlus Real-time PCR Instrument set at excitation wavelength
470 nm and emission wavelength of 570 nm over a temperature range from 11 to 80 ◦C ramped to 0.5 ◦C increments with
plateau times of 30 s. Measurements were performed in duplicates (n = 16–23). (B) Melting temperatures (Tm ± SEM ◦C)
were obtained by calculating the first derivatives of the fluorescence emission as a function of temperature (−dF/dT). A
significant decrease (### p < 0.0001) or increase (*** p < 0.0001) in Tm relative to WT protein was determined by one-way
ANOVA (Graphpad Prism) (n = 16–23).
ELISA data for binding of mAb 5D3 and 780A to the mutant forms of EPAC1∆DEP
in comparison with wild-type EPAC1∆DEP are shown in Figure 8. Results demonstrated
that the binding efficacy (Emax) of mAb 5D3 was significantly reduced (p < 0.05) by
mutants L273W and R279L in comparison to EPAC1∆DEP WT, where it dropped from
approximately 7.8 ± 0.6 (A.U.) to approximately 5.8 ± 0.3 (A.U.) (Figure 8A,C). In contrast,
the binding of Affimer 780A was significantly decreased by mutants L273W, D276R and
R279L (Figure 8F). It can therefore be concluded that while both mAb 5D3 and Affimer
780A share overlapping binding sites in the EPAC1 CNBD, the mode of interaction is
different and relies on distinct amino acids, notably D276 for Affimer A780A binding. This
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is confirmed by competition assays, where unlabelled mAb 5D3 is unable to inhibit binding
of labelled Affimer 780A to the EPAC1 CNBD (Figure 8F). In fact, there is a small, non-
significant potentiation of Affimer 780A binding, which suggests possible cooperativity of
binding of the two affinity agents on the CNBD.
Figure 8. Comparison of the relative binding affinities of Affimer 780A to mAb 5D3 to recombinant
EPAC1∆DEP WT and mutant proteins. GST-tagged recombinant (wild-type (WT) or mutant) protein
were added to glutathione-coated plates and incubated overnight at 4 ◦C. Serial dilutions of antibody
(A–C) mAb 5D3 (0.2–125 nM) and (D–F) Affimer 780A (0.004–4 µM) and incubated for one hour at
RT. Anti-His-tag or anti-mouse antibodies (1:10,000) were then added and incubated for a further
one hour at RT. The ELISA substrate was then added, and absorbance measurements (655 nm) were
taken after 30 min incubation at RT using a FLUOstar Omega Microplate reader. Data are normalized
as a fold change with the relative fluorescence associated with the lowest concentration of antibody
or Affimer set to 1 (arbitrary units (AU)). Error bars represent standard error of the mean (n = 3–5).
Significant increases in EC50 (** p < 0.005) or decrease in Emax (# p < 0.05) relative to EPAC1∆DEP
WT were determined by unpaired t-test (GraphPad Prism). (F) Competition ELISA assays to check
overlap between Affimer 780A and antibody 5D3 binding sites. Affinity reagents were used at
concentrations on 145 nM and 2 nM, respectively.
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3.4. Application of Identified Affimers in Immunoprecipitation Experiments
To test the ability of the top three EPAC1-selective Affimers, 780A, 380A and 414A to
immunoprecipitate (IP) EPAC1 or EPAC2 protein from cells, U2OS cells stably transfected
with EPAC1 (EPAC1 U2OS) or EPAC2 (EPAC2 U2OS) were used as a source of cellular
EPAC proteins. The performance of these Affimers was compared to EPAC1 specific mAB
5D3 and EPAC2 specific mAb 5B1 (Figure 9). In the immunoprecipitation experiments in
Figure 9, EPAC1 or EPAC2 proteins are indicated by an asterisk (*) at an approximately
100 kDa size and total EPAC1 or EPAC2 protein levels can be seen in lane one. The heavy
(H) and/or light (L) chains of Protein G Agarose and α-His-Tag Sepharose at approximately
46 and 25 kDa, respectively, could also be observed (Figure 9). In the EPAC1 U2OS cells, it
appeared that there were higher levels of EPAC1 protein in comparison to EPAC2 protein
in EPAC2 U2OS cells (Figure 9A vs. Figure 9B). As the negative control, IgG Ab did not
precipitate any EPAC1 or EPAC2 protein, but the light chain could be seen in lane two,
demonstrating that samples were loaded in these lanes (Figure 9).
Figure 9. Comparison of antibodies and Affimers for immunoprecipitation of EPAC1 and EPAC2 using. (A) EPAC1 and (B)
EPAC2 U20S cells were harvested in 0.5 mL of RIPA buffer, containing protease inhibitor cocktail, and lysed for 30 min by
rotation at 4 ◦C. Extracts were centrifuged and cell lysates were collected, including inputs (total EPAC protein) (lane 1).
To each cell lysate, 4 µg of rabbit IgG antibody (lane 2), 1.4 µg of 5D3 (A: lane 3) or 2.5 µg of 5B1 antibody (B: lane 3), or
2.6 µg of Affimer: 780A (lane 4), 380A (lane 5) and 414A (lane 6) were added and incubated with rotation for one hour
(4 ◦C) before adding 40 µL of Protein G Agarose (lanes 2–4) or α-His-Tag Sepharose® beads (lanes 5–6). After a one-hour
incubation at 4 ◦C, with rotation, antibody-bead complexes were collected while Affimer-bead complexes were collected
after an overnight incubation at 4 ◦C. Beads were then washed five times with 0.5 mL RIPA buffer using centrifugation for
the collection of beads. Samples were heated in electrophoresis sample buffer for five minutes at 95 ◦C and analyzed by
Western blotting where 15 and 30 µL of input and isolated immunoprecipitated proteins, respectively, per well from EPAC1
or EPAC2 U20S cells were separated by SDS-PAGE and probed with (A) 5D3 antibody or (B) 5B1 and α-mouse primary and
secondary antibodies, respectively, as described in Materials and Methods. Total EPAC Protein (*), and heavy (H) and light
(L) chain bands are indicated. Protein markers (kDa) are also indicated.
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From these IP results, it could clearly be seen that mAb 5D3 successfully precipitated
EPAC1 proteins from cells (Figure 9A), whereas mAb 5B1 was unable to precipitate EPAC2
protein (Figure 9B). Similarly, all three Affimers successfully precipitated EPAC1 protein,
as seen in lanes four to six, but did not precipitate EPAC2 protein (Figure 9). The lack of
EPAC2 protein in these wells was not due to sample loading error as H and L chains of
the α-His-Tag Sepharose could be seen (Figure 9). No differences in precipitated EPAC1
protein levels were observed between the Affimers, but the Affimers did precipitate less
EPAC1 protein than mAb 5D3 (Figure 9). Therefore, although Affimers 780A, 380A and
414A continued to show selective interaction with EPAC1 in U2OS cells, mAb 5D3 Ab was
still a more potent binder. Nevertheless, all three Affimers showed a selective interaction
with EPAC1 over EPAC2, which agrees with the protein interaction ELISA experiments
shown above.
3.5. Application of EPAC1 Affimers to Confocal Microscopy
Having demonstrated that Affimers can interact with cellular EPAC1 in immunopre-
cipitation experiments, we next asked whether they could be useful reagents for confocal
localization experiments in cells. For this, co-transfection experiments were carried out
to determine the co-localization of wild-type EPAC1 and Affimer 780A in non-stimulated
(-007) and stimulated (+007) COS1 cells. In Figure 10, FLAG-tagged wild-type EPAC1
(WT-EPAC1-FLAG) can be observed in green in the top images and displays a diffuse
pattern throughout the cell, which is not affected by 007 treatment. This is very similar
to the distribution of mCherry-tagged Affimer 780A-mCherry (780A-mCherry, shown in
red) in cells, which is again unaffected by 007 treatment (Figure 9; third pane from the top).
Thus, although Affimer 780A and wild-type EPAC1 show similar patterns of distribution
throughout the cell, the experiment lacks the resolution to show co-localization of the
co-transfected poteins.
To address this, we next examined the localization of Affimer 780A in COS1 cells co-
transfected with FLAG-tagged EPAC1 (K212R; Figure 10), which represent a mis-targeting
mutant of EPAC1, previously identified in the Baillie laboratory, to obtain improved resolu-
tion of any co-localization. We observed that the EPAC1-(K212R) mutant was excluded
from the nuclei of both non-stimulated and 007-stimulated COS1 cells as seen in Figure 9.
The localization of the EPAC1 mutant was found to be distinctively punctate throughout
the cell following stimulation in 007 (Figure 10; second panel from top). In the merged im-
age of a non-stimulated cells, some co-localization of Affimer 780A and the EPAC1-(K212R)
mutant was observed in areas out-with the nucleus (merge 780A/K212R left). However,
co-localization could be seen more clearly in the stimulated cells in the punctate areas of
the cytosol (merge 780A/K212R right). This suggests that Affimer 780A can co-localize
with the mistargeted EPAC1-(K212R) mutant in 007-stimulated cells.
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Figure 10. Localization of Affimer 780A-mCherry with co-transfected wild-type and mutant (K212R) EPAC1 in COS1
cells. COS1 cells were transiently co-transfected with 780A-mCherry and WT-EPAC1-FLAG or EPAC1-(K212R)-FLAG
780A-mCherry and then stimulated ± 100 µM of 007 for 15 min (37 ◦C, 5% (v/v) CO2). Following fixation, permeabilization
and blocking cells were then incubated for one hour each with α-FLAG and goat α-mouse IgG (Alexa Fluor 488 conjugated)
primary and secondary antibodies, respectively. Coverslips were then mounted onto glass slides using Prolong™ Glass
Antifade Mountant and analyzed on a Leica TCS SP8 STED 3X confocal microscope with a Leica HC PL APO C52 63×water
objective. Samples were excited using a Supercontinuum White laser at 488 and 580 nm for Alexa Fluor 488 and mCherry
proteins, respectively, and were detected using a Leica HyD hybrid detector with detection windows of 500–550 nm (Alexa
Fluor 488) and 590–650 nm (mCherry). Scale bar: 100 nm.
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4. Discussion
To provide a target to generate EPAC1-selective Affimers for phage display, a purifica-
tion protocol for recombinant EPAC1∆DEP protein was optimized to obtain protein that
was at least 90% pure. In general, the optimized protocol produced approximately 1 mg
EPAC1∆DEP per liter of culture. Purified EPAC1∆DEP was biotinylated and used as a
target in phage-display screens to identify candidate EPAC1-selective Affimers that were
subjected to final functional assessment using a fluorescent-based protein interaction screen.
Phage-display screens were carried out in the presence of the EPAC-selective agonists,
007, or the antagonist, CE3F4, and sequencing of interacting phage revealed nine unique
Affimers, five of which were established as being EPAC1-positive binders in orthogonal
screens. Despite the presence of 007 or CE3F4 during phage-display screening, the isolated
Affimers did not appear to discriminate between the ligand bound and ligand-free forms
of EPAC1.
The binding characteristics of the five Affimers, named 380A, 414A, 604A, 748A and
780A, were further characterized for their ability to interact with EPAC1, using different
solid and solution phase in vitro assays. From these assays, Affimers 780A, 380A and 414A
were identified using dot blots and ELISA assays as the top three binders that showed
selectivity for recombinant EPAC1∆DEP and EPAC1-CNBD protein, over EPAC2, although
their relative binding affinities were much lower than the pre-existing EPAC1 mAb, 5D3.
In addition, from these experiments, it was clear that Affimer 780A interacted equally
well with the active and inactive conformations of EPAC1, as provoked by ligand binding.
Affimer A780 therefore presents technical advantages over mAb 5D3 in that it is not
conformation selective, whereas 5D3 favors interaction with the active conformation of
EPAC1.
The potential interaction sites of Affimer 780A on EPAC1 were first investigated
using ELISA and TSA assays to assess interaction of the Affimer with four CNBD mutants
of recombinant EPAC1∆DEP (L273W, D276R, R279L and F300D), which were originally
used to identify the binding epitope for mAb 5D3 in the EPAC1 CNBD [31]. ELISA
assays revealed that the binding of Affimer 780A was significantly reduced by D276R and
R279L mutants, compared to WT EPAC1, whereas the binding efficacy of mAb 5D3 was
significantly impaired by mutants L273W and D276R. Recombinant F300D was found to be
in a non-native form by TSA. Thus, although Affimer 780A and mAb 5D3 interact within
the same discrete region within the EPAC1 CNBD, it appears that their binding mode are
subtly different, that, and the comparative size differences between 780A and mAb 5D3,
may go some way to explain the differences in conformational selectivity between the two
affinity agents.
Having determined that Affimer 780A is an affective binder for EPAC1, in cell interac-
tion assays were carried out next. Using immunoprecipitation assays, the top three Affimer
binders were all found to selectively precipitate EPAC1 protein from U2OS cells expressing
EPAC1, but not EPAC2. Moreover, in agreement with in vitro studies, the Affimers did
not show preferential interaction with the active form of EPAC1, in comparison with mAb
5D3. Next confocal microscopy experiments were used to visualize the expression of a
protein chimera of Affimer 780A with fluorescent mCherry protein in COS1 cells. From
these experiments it was found that Affimer 780A localized to the nuclei of COS1 cells,
whether or not EPAC1 was pharmacologically activated by treatment of cells with 007.
Furthermore, Affimer 780A was observed to co-localize with FLAG-tagged EPAC1 and
a mis-targeted mutant of EPAC1, K212R, predominantly at punctate loci throughout the
cytosolic regions of COS1 cells, following 007 treatment.
Recombinant protein scaffolds, such as Affimers, can and have been used to observe
direct target binding. Affimers are not only small proteins (12–14 kDa), allowing for good
penetration of cells, but can also be easily labelled with fluorescent molecules at specific
sites [37,38]. This offers improved resolution, providing a more confident assessment of
the localization of an Affimer with its specific target, such as EPAC1 in the case of Affimer
780A. Through confocal microscopy studies, Affimer 780A was shown to localize with
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overexpressed EPAC1, with or without 007 stimulation, further demonstrating that the
Affimer does not favor the active or inactive conformations of EPAC1, unlike mAb 5D3,
which interacts selectively with active EPAC1 [23]. In addition, the co-localization of
Affimer 780A with a mis-targeting EPAC1 mutant (K212R) confirms that the Affimer binds
to EPAC1 in cells regardless of location. Furthermore, the subcellular co-localization of
the Affimer with EPAC1 predominantly in the nuclear and perinuclear regions here agree
with previous studies, using several different cell types, providing further confidence that
Affimer 780A interacts with EPAC1 in cells. For example, in COS-7 cells transfected with
GFP-tagged EPAC1 protein, fluorescent confocal microscopy showed an association of
EPAC1 with the nucleus and along the nuclear membrane [17]. In addition, using an EPAC1
FRET sensor, where EPAC1 was sandwiched between two different fluorescent proteins,
active EPAC1 was observed to co-localize to membranes and the cytosol, but particularly
at the nuclear envelope and perinuclear region in four different cell lines tested, including
HEK293 and NIE-115 neuroblastoma cell lines [39]. Moreover, in an immunocytochemistry
(ICC) study, using transfected FLAG-tagged EPAC1 in COS1 cells, the immunoreactivity of
EPAC1, was also seen to associate distinctly with the perinuclear region of COS1 cells [18].
Using both live cell fluorescent confocal experiments and FRET imaging of HEK293 cells, it
was also observed that active EPAC1 associates with the nuclear envelope, nucleus, PM,
endomembranes and cytosol [22]. In this case, however, when cells were stimulated with
007, there was a redistribution of a small subfraction of EPAC1 to the PM [22], which is
consistent with what was observed here. Finally, HEK293T cells overexpressing EPAC1-
FLAG and immunostained with mAB 5D3 also showed that active EPAC1 associated with
the perinuclear region of cells [23]. The fact that the localization of Affimer 780A-mCherry
in COS1 cells observed in this project agree with results from the studies described above,
suggests that Affimer 780A has the potential to be used as a probe for microscopy studies
involving EPAC1.
5. Conclusions
Successive phage-display screens were used to identify nine potential EPAC1-selective
Affimer candidates, three of which were confirmed as being EPAC1 binders using a range
of in vitro assays. From these three, Affimer 780A was identified as being the best EPAC1
binder by dot bot and protein interaction ELISA assays. Little interaction with EPAC2
was observed in these assays. Affimer 780A was found to interact favorably with either
the active or inactive conformations of EPAC1. Mutagenesis studies revealed a potential
interaction site for Affimer 780A within the CNBD of EPAC1. As such, Affimer 780A was
able to interact with and precipitate EPAC1, but not EPAC2, protein from cell extracts and,
when tagged with fluorescent mCherry protein, Affimer 780A, was found to co-localize
with both wild-type EPAC1 and a non-targeting EPAC1 mutant (K212R), predominantly in
the perinuclear and cytosolic regions of cells, respectively. Overall, Affimer 780A represents
a first-in-class selective binder for EPAC1 for use in biochemical and cell biology studies of
cyclic AMP signaling. Future work will be aimed at improving the affinity of Affimer A780
towards EPAC1 through selective mutation of the Affimer binding site and also generate
Affimers to the N- and C-termini of EPAC1. By improving the affinity towards EPAC1 and
identifying further interactions sites we hope to extend the usefulness of EPAC1 Affimers
for fluorescent microscopy and other applications, including modulation of EPAC1 activity
and intracellular targeting.
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